Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 2/20 | 0.65 |
| ▸ | IDO1 | P14902 | 7/20 | 0.46 |
| ▸ | TBXAS1 | P24557 | 8/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.38 |
| ▸ | AURKA | O14965 | 1/20 | 0.38 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.38 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.38 |
| ▸ | ABL1 | P00519 | 1/20 | 0.38 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.38 |
| ▸ | LCK | P06239 | 1/20 | 0.38 |
| ▸ | FYN | P06241 | 1/20 | 0.38 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.38 |
| ▸ | PIM1 | P11309 | 1/20 | 0.38 |
| ▸ | PRKACA | P17612 | 1/20 | 0.38 |
| ▸ | LTK | P29376 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.38 |
| ▸ | FLT3 | P36888 | 1/20 | 0.38 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.38 |
| ▸ | CDK8 | P49336 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3535788 | 0.98 | CYP11B2 (0.63) | CYP11B2IDO1TBXAS1MAPK14AURKA | |
| SCHEMBL3536508 | 0.83 | CYP11B2 (0.55) | CYP11B2IDO1TBXAS1MAPK14AURKA | |
| Hydrochloric Acid SCHEMBL3537661 | 0.81 | CYP11B2 (0.54) | CYP11B2IDO1TBXAS1MAPK14AURKA | |
| SCHEMBL3534128 | 0.79 | CYP11B2 (1.00) | CYP11B2IDO1TBXAS1KDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL3539978 | 0.78 | CYP11B2 (0.97) | CYP11B2IDO1TBXAS1KDM4EALDH1A1 | |
| SCHEMBL9261340 | 0.76 | CYP11B2 (0.60) | CYP11B2IDO1TBXAS1 | |
| SCHEMBL21060527 | 0.72 | IDO1 (0.66) | CYP11B2IDO1TBXAS1PTGS1PTGS2 | |
| SCHEMBL21323991 | 0.72 | CYP11B2 (0.55) | CYP11B2TBXAS1DYRK1AKDM4EALDH1A1 | |
| SCHEMBL19915978 | 0.71 | IDO1 (0.54) | CYP11B2IDO1KDM4E | |
| SCHEMBL19915972 | 0.71 | IDO1 (0.54) | CYP11B2IDO1TBXAS1MAPK14LCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7713991-B2 | Imidazo[[1, 5-A] pyridine derivatives and methods for treating aldosterone mediated diseases | NOVARTIS AG (CH) | 2010-05-11 | — | — | US | claimed |
| EP-1565463-B1 | IMIDAZO[1,5A] PYRIDINE DERIVATIVES AND METHODS FOR TREATING ALDOSTERONE MEDIATED DISEASES | NOVARTIS AG (CH) | 2008-06-11 | — | — | EP | claimed |
| US-20070197582-A1 | IMIDAZO[[1, 5-A] PYRIDINE DERIVATIVES AND METHODS FOR TREATING ALDOSTERONE MEDIATED DISEASES | NOVARTIS AG (CH) | 2007-08-23 | — | — | US | claimed |
| US-7223866-B2 | Imidazo[1,5-a]pyridine derivatives and methods for treating aldosterone mediated diseases | NOVARTIS AG (CH) | 2007-05-29 | — | — | US | claimed |
| US-20060058342-A1 | Imidazo[1,5-a]pyridine derivatives and methods for treating aldosterone mediated diseases | NOVARTIS AG (CH) | 2006-03-16 | — | — | US | claimed |
| JP-2006508970-A | — | — | 2006-03-16 | — | — | JP | claimed |
| EP-1565463-A1 | IMIDAZO[1,5A]PYRIDINE DERIVATIVES AND METHODS FOR TREATING ALDOSTERONE MEDIATED DISEASES | Novartis AG (CH) | 2005-08-24 | — | — | EP | claimed |
| WO-2004046145-A1 | IMIDAZO[1, 5A]PYRIDINE DERIVATIVES AND METHODS FOR TREATING ALDOSTERONE MEDIATED DISEASES | NOVARTIS AG (CH) | 2004-06-03 | — | — | WO | claimed |
| US-7713991-B2 | Imidazo[[1, 5-A] pyridine derivatives and methods for treating aldosterone mediated diseases | NOVARTIS AG (CH) | 2010-05-11 | — | — | US | disclosed |
| US-7713991-B2 | Imidazo[[1, 5-A] pyridine derivatives and methods for treating aldosterone mediated diseases | NOVARTIS AG (CH) | 2010-05-11 | — | — | US | disclosed |
| US-7713991-B2 | Imidazo[[1, 5-A] pyridine derivatives and methods for treating aldosterone mediated diseases | NOVARTIS AG (CH) | 2010-05-11 | — | — | US | disclosed |
| EP-1565463-B1 | IMIDAZO[1,5A] PYRIDINE DERIVATIVES AND METHODS FOR TREATING ALDOSTERONE MEDIATED DISEASES | NOVARTIS AG (CH) | 2008-06-11 | — | — | EP | disclosed |
| EP-1565463-B1 | IMIDAZO[1,5A] PYRIDINE DERIVATIVES AND METHODS FOR TREATING ALDOSTERONE MEDIATED DISEASES | NOVARTIS AG (CH) | 2008-06-11 | — | — | EP | disclosed |
| US-20070197582-A1 | IMIDAZO[[1, 5-A] PYRIDINE DERIVATIVES AND METHODS FOR TREATING ALDOSTERONE MEDIATED DISEASES | NOVARTIS AG (CH) | 2007-08-23 | — | — | US | disclosed |
| US-7223866-B2 | Imidazo[1,5-a]pyridine derivatives and methods for treating aldosterone mediated diseases | NOVARTIS AG (CH) | 2007-05-29 | — | — | US | disclosed |
| US-7223866-B2 | Imidazo[1,5-a]pyridine derivatives and methods for treating aldosterone mediated diseases | NOVARTIS AG (CH) | 2007-05-29 | — | — | US | disclosed |
| US-20060058342-A1 | Imidazo[1,5-a]pyridine derivatives and methods for treating aldosterone mediated diseases | NOVARTIS AG (CH) | 2006-03-16 | — | — | US | disclosed |
| EP-1565463-A1 | IMIDAZO[1,5A]PYRIDINE DERIVATIVES AND METHODS FOR TREATING ALDOSTERONE MEDIATED DISEASES | Novartis AG (CH) | 2005-08-24 | — | — | EP | disclosed |
| WO-2004046145-A1 | IMIDAZO[1, 5A]PYRIDINE DERIVATIVES AND METHODS FOR TREATING ALDOSTERONE MEDIATED DISEASES | NOVARTIS AG (CH) | 2004-06-03 | — | — | WO | disclosed |
| WO-2004046145-A1 | IMIDAZO[1, 5A]PYRIDINE DERIVATIVES AND METHODS FOR TREATING ALDOSTERONE MEDIATED DISEASES | NOVARTIS AG (CH) | 2004-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058342-A1 | Imidazo[1,5-a]pyridine derivatives and methods for treating aldosterone mediated diseases | CYP11B1, CYP17A1, CYP27A1 | CYP11B2 8/4885IDO1 695/4885TBXAS1 181/4885 |
| US-20070197582-A1 | IMIDAZO[[1, 5-A] PYRIDINE DERIVATIVES AND METHODS FOR TREATING ALDOSTERONE MEDIATED DISEASES | CYP11B1, CYP27A1, CYP17A1 | CYP11B2 7/4885IDO1 729/4885TBXAS1 177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.